We have successfully illustrated that targeting IL-6R could be an alternative way to suppress IL-6/STAT3 pathway in breast cancer and demonstrate the usage of TCZ could reduce tamoxifen resistance in breast cancer. This evidence concerns the gene STAT3 and breast carcinoma.